Should I buy NeoGenomics Laboratories, Inc. (NEO) stock or is it too late?
⭐ The most reliable of them, either direction: Benchmark — 55% of its targets hit on this sector (69 calls tested). It aims for $16 (-4.0 %), call made on July 25, 2026, maturing on July 25, 2027 (81 d ago).
Firm-by-firm track record on NeoGenomics Laboratories, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Piper Sandler | 78 % | +37.0 % | 9 | $13 -22% |
| BTIG | 75 % | +27.6 % | 8 | $28 +68% |
| Needham | 48 % | +11.3 % | 29 | $22 +32% |
| Benchmark | 67 % | -1.1 % | 9 | $16 -4% |
| Stephens & Co. | 60 % | -7.2 % | 5 | $11 -34% |
| Goldman Sachs | 25 % | -12.6 % | 8 | $10 -40% |
| Raymond James | 83 % | +19.5 % | 12 | — |
| SVB Leerink | 50 % | -1.4 % | 8 | — |
✅ Reasons to believe
- 100% of analysts rate it a buy (Buy consensus, 6 ratings) — a sign of market conviction.
- Median price target $21, i.e. +26% from the current price ($17).
⚠️ Reasons to hesitate
- Even the most reliable firm on NEO, Piper Sandler (78% hit rate, 9 scored calls), only targets $13 (call made on February 24, 2026, maturing on February 24, 2027) (-22%) in its most recent call. The stock may already have run past its target.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
- A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.
The analyst consensus on NEO
Median target $21 (+26%) · 6 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in NeoGenomics Laboratories, Inc. now?
We won't decide for you. The facts: 100% of analysts rate it a buy, median target $21 (+26%), and Piper Sandler (most reliable on NEO, 78%) targets $13. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in NeoGenomics Laboratories, Inc.?
Not according to analysts: the median target ($21) is still +26% above the current price ($17) (most reliable on NEO: Piper Sandler, 78%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is NeoGenomics Laboratories, Inc. still worth investing in?
It depends on the gap between the price ($17) and its estimated value: analysts target $21 on median (+26%), with 100% buys (most reliable on NEO: Piper Sandler, 78%). Cross-check with their real reliability on NEO and the cautions above. Information, not advice.
What's the main risk in buying NEO?
Even the most reliable firm on NEO, Piper Sandler (78% hit rate, 9 scored calls), only targets $13 (call made on February 24, 2026, maturing on February 24, 2027) (-22%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full NeoGenomics Laboratories, Inc. profile (consensus, analyst reliability, price target, performance).